Stefano Ballestri

List of Publications by Year
in descending order

53	5,543	126708	174990
papers	citations	33 h-index	52 g-index

53	53	53	8017
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome. Digestive and Liver Disease, 2015, 47, 181-190.	0.4	551
2	Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. Hepatology, 2019, 70, 1457-1469.	3.6	547
3	Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 936-944.	1.4	537
4	Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 830-840.	1.4	467
5	NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. Advances in Therapy, 2017, 34, 1291-1326.	1.3	380
6	Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Digestive and Liver Disease, 2015, 47, 997-1006.	0.4	368
7	Nonalcoholic fatty liver disease and aging: Epidemiology to management. World Journal of Gastroenterology, 2014, 20, 14185.	1.4	227
8	Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2014, 20, 1724.	1.4	207
9	Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. Gut, 2016, 65, 861-869.	6.1	207
10	Ultrasonographic fatty liver indicator, a novel score which rules out <scp>NASH</scp> and is correlated with metabolic parameters in <scp>NAFLD</scp>. Liver International, 2012, 32, 1242-1252.	1.9	155
11	Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications. International Journal of Environmental Research and Public Health, 2019, 16, 3104.	1.2	135
12	The independent predictors of nonâ€alcoholic steatohepatitis and its individual histological features.. Hepatology Research, 2016, 46, 1074-1087.	1.8	124
13	Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis, 2014, 232, 99-109.	0.4	113
14	Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases. Metabolism: Clinical and Experimental, 2017, 72, 57-65.	1.5	110
15	Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. Expert Review of Gastroenterology and Hepatology, 2015, 9, 603-627.	1.4	102
16	Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences, 2016, 61, 1246-1267.	1.1	99
17	Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World Journal of Gastroenterology, 2016, 22, 9674.	1.4	93
18	Pathogenesis and significance of hepatitis C virus steatosis: An update on survival strategy of a successful pathogen. World Journal of Gastroenterology, 2014, 20, 7089.	1.4	81

#	Article	IF	Citations
19	Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Review of Gastroenterology and Hepatology, 2015, 9, 629-650.	1.4	72
20	A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?. Acta Diabetologica, 2019, 56, 385-396.	1.2	71
21	Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels?. Internal and Emergency Medicine, 2013, 8, 297-305.	1.0	66
22	The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans. Advances in Therapy, 2016, 33, 291-319.	1.3	62
23	Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease. Diagnostics, 2021, 11, 98.	1.3	59
24	A â€œsystems medicineâ€•approach to the study of non-alcoholic fatty liver disease. Digestive and Liver Disease, 2016, 48, 333-342.	0.4	56
25	Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease. Expert Review of Gastroenterology and Hepatology, 2011, 5, 253-263.	1.4	53
26	Fatty liver, carotid disease and gallstones: A study of age-related associations. World Journal of Gastroenterology, 2006, 12, 5826.	1.4	53
27	Clinical relevance of liver histopathology and different histological classifications of NASH in adults. Expert Review of Gastroenterology and Hepatology, 2018, 12, 351-367.	1.4	47
28	Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity?. Digestive and Liver Disease, 2019, 51, 462-470.	0.4	44
29	Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative Review. Advances in Therapy, 2020, 37, 1910-1932.	1.3	40
30	Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis. World Journal of Gastroenterology, 2017, 23, 1458.	1.4	38
31	A critical appraisal of the use of ultrasound in hepatic steatosis. Expert Review of Gastroenterology and Hepatology, 2019, 13, 667-681.	1.4	38
32	Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infectionâ€”Liver: The â€œMusketeerâ€•in the Spotlight. International Journal of Molecular Sciences, 2016, 17, 355.	1.8	36
33	Treatment of Atherogenic Liver Based on the Pathogenesis of Nonalcoholic Fatty Liver Disease: A Novel Approach to Reduce Cardiovascular Risk?. Archives of Medical Research, 2011, 42, 337-353.	1.5	35
34	Extra-hepatic manifestations and complications of nonalcoholic fatty liver disease. Future Medicinal Chemistry, 2019, 11, 2171-2192.	1.1	30
35	Hepatitis C Virus-Infected Patients Are â€˜Sparedâ€™ from the Metabolic Syndrome but Not from Insulin Resistance. A Comparative Study of Nonalcoholic Fatty Liver Disease and Hepatitis C Virus-Related Steatosis. Canadian Journal of Gastroenterology & Hepatology, 2009, 23, 273-278.	1.8	27
36	Relationship of Serum Fetuin-A Levels with Coronary Atherosclerotic Burden and NAFLD in Patients Undergoing Elective Coronary Angiography. Metabolic Syndrome and Related Disorders, 2013, 11, 289-295.	0.5	26

#	Article	IF	Citations
37	â€œ Not all forms of NAFLD were created equal â€• Do metabolic syndrome-related NAFLD and PNPLA3 -related NAFLD exert a variable impact on the risk of early carotid atherosclerosis?. Atherosclerosis, 2017, 257, 253-255.	0.4	26
38	Perspectives of nonalcoholic fatty liver disease research: a personal point of view. , 2020, 1, 85-107.		23
39	Human Immunodeficiency Virus Is the Major Determinant of Steatosis and Hepatitis C Virus of Insulin Resistance in Virus-associated Fatty Liver Disease. Archives of Medical Research, 2011, 42, 690-697.	1.5	22
40	Inflammatory hepatocellular adenomatosis, metabolic syndrome, polycystic ovary syndrome and non-alcoholic steatohepatitis: Chance tetrad or association by necessity?. Digestive and Liver Disease, 2014, 46, 288-289.	0.4	19
41	Do Nonalcoholic Fatty Liver Disease and Fetuin-A Play Different Roles in Symptomatic Coronary Artery Disease and Peripheral Arterial Disease?. Diseases (Basel, Switzerland), 2018, 6, 17.	1.0	15
42	Polymorphism in the Farnesyl Diphosphate Farnesyl Transferase 1 Gene and Nonalcoholic Fatty Liver Disease Severity. Gastroenterology, 2011, 140, 1694-1695.	0.6	14
43	Magnetic Resonance for Quantitative Assessment of Liver Steatosis: A New Potential Tool to Monitor Antiretroviral-Drug-Related Toxicities. Antiviral Therapy, 2012, 17, 965-971.	0.6	11
44	Do diabetes and obesity promote hepatic fibrosis in familial heterozygous hypobetalipoproteinemia?. Internal and Emergency Medicine, 2009, 4, 71-73.	1.0	10
45	Semi-Quantitative Ultrasonographic Evaluation of NAFLD. Current Pharmaceutical Design, 2020, 26, 3915-3927.	0.9	9
46	Nonalcoholic fatty liver disease activity score and Brunt's pathologic criteria for the diagnosis of nonalcoholic steatohepatitis: What do they mean and do they agree?. Hepatology, 2011, 53, 2142-2143.	3.6	8
47	Primary lymphoma of the spleen mimicking simple benign cysts: contrast-enhanced ultrasonography and other imaging findings. Journal of Medical Ultrasonics (2001), 2015, 42, 251-255.	0.6	7
48	Nonalcoholic Fatty Liver Disease in HIV-Infected Persons: Epidemiology and the Role of Nucleoside Reverse Transcriptase Inhibitors. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 53, 278.	0.9	6
49	Sofosbuvir-based therapy cures hepatitis C virus infection after prior treatment failures in a patient with concurrent lymphoma. Journal of Clinical Virology, 2015, 69, 74-77.	1.6	6
50	The neck-liver axis. Madelung disease as further evidence for an impact of body fat distribution on hepatic histology. Hepatology, 2007, 47, 361-362.	3.6	5
51	Hepatocellular carcinoma in a patient treated with efalizumab for psoriasis. Hepatology Research, 2012, 42, 945-945.	1.8	3
52	NAFLD, Hepatotropic Viruses, and Cardiometabolic Risk. Hepatology, 2017, 65, 2122-2123.	3.6	2
53	Do ultrasonographic semiquantitative indices predict histological changes in <scp>NASH</scp> irrespective of steatosis extent?. Liver International, 2015, 35, 2340-2341.	1.9	1